Also known as: FST, Activin-Binding Protein, FST-344, FST-315, FST-288
Muscle growth via myostatin inhibition (gene therapy for muscular dystrophies; recombinant protein for research)
Amount
Gene therapy: 6 x 10^11 vg/kg per leg (single administration); Recombinant protein: 100-200 mcg SC daily
Frequency
Gene therapy: single administration; Recombinant protein: once daily for 10-30 day cycles
Duration
Gene therapy: one-time treatment; Recombinant protein: 10-20 days, repeated every 6 months
Route
IMSchedule
Gene therapy: single administration; Recombinant protein: once daily for 10-30 day cycles
Timing
No specific time of day for either approach
Duration
Gene therapy: one-time treatment; Recombinant protein: 10-20 days, repeated every 6 months
Repeatable
Single cycle
Course-based protocol with rest periods
Storage: AAV gene therapy vectors require storage at -80C or below. Recombinant follistatin protein should be stored lyophilized at -20C or below. Reconstituted solutions at 2-8C, use within specified timeframe.
CBC with differential
When: Baseline
Why: Baseline blood counts
CMP
When: Baseline
Why: Liver and kidney function
CK (creatine kinase)
When: Baseline
Why: Baseline muscle damage marker
FSH and reproductive hormones (women)
When: Baseline
Why: Follistatin regulates FSH; inhibition may affect reproductive axis
Anti-AAV1 antibodies (gene therapy)
When: Baseline
Why: Pre-existing antibodies may reduce transduction efficiency
CK
When: 2 weeks
Why: Monitor for muscle damage
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Follistatin is a naturally occurring glycoprotein synthesized in nearly all tissues of higher animals. It was originally identified as an activin-binding protein that suppresses follicle-stimulating hormone (FSH) secretion from the anterior pituitary, hence its name. Follistatin functions primarily by binding and neutralizing members of the TGF-beta superfamily, with particular affinity for activin A, activin B, and myostatin (GDF-8).
Three major isoforms of follistatin are produced through alternative splicing of the FST gene: FST-288, FST-303, and FST-315. FST-315 is the predominant circulating form, accounting for approximately 95% of all follistatin in the blood. FST-288 has the highest affinity for heparan sulfate proteoglycans and tends to remain bound to cell surfaces. The FST-344 precursor (containing a 29-residue C-terminal extension that is cleaved to generate FST-315) has been used in gene therapy research due to its favorable biological properties.
Follistatin's most therapeutically relevant function is its ability to bind and neutralize myostatin, the primary negative regulator of skeletal muscle mass. Myostatin normally signals through activin receptor type IIB (ActRIIB) to activate Smad2/3 signaling, which suppresses muscle protein synthesis and promotes muscle atrophy. By sequestering myostatin, follistatin removes this brake on muscle growth, allowing enhanced muscle hypertrophy.
The structural basis for this interaction has been elucidated through crystallography. Follistatin wraps around the myostatin dimer, occluding the receptor-binding interface and preventing myostatin from engaging its receptor. This inhibition is essentially irreversible under physiological conditions, as the follistatin-myostatin complex is cleared from circulation.
Follistatin also binds activin A and B with high affinity. Activins play roles in reproductive biology, inflammation, fibrosis, and metabolism. Follistatin-mediated activin neutralization affects FSH secretion, hepatic function, and inflammatory responses, contributing to the pleiotropic effects observed with follistatin overexpression.
The most advanced clinical application of follistatin is in gene therapy for muscular dystrophy. Mendell and colleagues conducted a Phase 1/2a clinical trial using AAV1-delivered follistatin (AAV1.CMV.huFS344) for Becker muscular dystrophy (PMID: 25322757). Intramuscular injection into the quadriceps muscles showed improved ambulatory function, with the high-dose cohort showing increased 6-minute walk test distance by up to 108 meters. Histological analysis demonstrated reduced endomysial fibrosis and muscle fiber hypertrophy.
A subsequent trial in sporadic inclusion body myositis using the same AAV1-FS344 vector also showed functional improvements. These results have advanced follistatin gene therapy into further clinical development.
Follistatin is being investigated for age-related muscle loss (sarcopenia) and disease-related muscle wasting (cachexia). Preclinical studies consistently demonstrate that follistatin overexpression or administration produces significant muscle hypertrophy, even in the absence of exercise.
Follistatin's broad activity against multiple TGF-beta superfamily members means that therapeutic use must carefully consider off-target effects. Activin inhibition can affect reproductive function, and long-term consequences of systemic myostatin inhibition are not fully characterized. Gene therapy approaches offer the advantage of localized delivery to target muscles, potentially reducing systemic exposure.
While gene therapy trials have produced encouraging results, sample sizes have been small and follow-up periods limited. The durability of AAV-mediated follistatin expression, the potential for immune responses against the transgene or vector, and the long-term safety of chronic myostatin inhibition require further investigation in larger trials.
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy, published in Molecular Therapy (Mendell JR et al., 2015; PMID: 25322757):
First-in-human gene therapy trial using AAV1-delivered follistatin for Becker muscular dystrophy, showing improved ambulatory function and histological improvements.
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes, published in Molecular Therapy (Mendell JR et al., 2017; PMID: 28279643):
Gene therapy trial of AAV1-FS344 in sporadic inclusion body myositis patients showing functional improvements in walking and muscle strength.
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease, published in Muscle and Nerve (Rodino-Klapac LR et al., 2009; PMID: 19208403):
Review of preclinical evidence supporting follistatin-mediated myostatin inhibition as a therapeutic strategy for muscular dystrophies.
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 30+ community reports
View community protocolsResearch-grade suppliers verified by our scoring methodology.
ACE-031: ActRIIB-Fc myostatin inhibitor for muscle wasting. Covers mechanism, Duchenne dystrophy trials, dosing, side effects, and clinical status.
Apitegromab (SRK-015): anti-promyostatin antibody by Scholar Rock. Phase 3 SAPPHIRE met primary endpoint in SMA. Also studied for lean mass in obesity.
Bimagrumab (BYM338): activin type II receptor antibody for muscle preservation and fat loss. BELIEVE trial showed 22.1% weight loss with semaglutide combo.
GDF-8 (Myostatin): Muscle growth negative regulator guide. Covers TGF-beta signaling, double-muscling mutations, inhibitor therapies, and research.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Research review of peptides targeting sarcopenia and age-related muscle loss, including myostatin inhibitors, growth factors, and GH secretagogues with clinical trial data.
A research review comparing bimagrumab, trevogrumab, and apitegromab โ three anti-myostatin antibodies in clinical development for muscle preservation, obesity, and spinal muscular atrophy.
Comprehensive guide to peptides for muscle growth and preservation โ myostatin inhibitors (follistatin, bimagrumab, trevogrumab, apitegromab), IGF-1 pathway (IGF-1 LR3, MGF), and growth hormone secretagogues (ibutamoren, HGH) with clinical evidence and body recomp strategies.
Myostatin inhibitors and muscle growth peptides โ follistatin, ACE-031, GDF-8, IGF-1 LR3, and MGF โ mechanisms and clinical evidence.
Related content you may find interesting